Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimising Neurosonography in the NICU: An Audit of 130 Cases and Proposal of a Referral and Reporting Protocol.

Cureus·2026
Same author

Chemical and biological cargo on microplastics: current evidence for the Trojan-horse pathway to human exposure.

Environmental research·2026
Same author

Analysis of structure and stability of Leishmania donovani Rab5a and Rab5b.

International journal of biological macromolecules·2026
Same author

Identification and validation of natural product-based KRAS<sup>G12D</sup> inhibitors through structure-based virtual screening, molecular dynamics simulation, and in vitro studies.

Molecular diversity·2026
Same author

Small extracellular vesicles in clinical Cancer research - A quantitative proteomics perspective.

Journal of proteomics·2026
Same author

BDNF- Dysregulation as a Neurobiological Bridge between Polycystic Ovarian Syndrome and Autism Spectrum Disorder.

ACS chemical neuroscience·2026

Related Experiment Video

Updated: Jun 4, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.5K

Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding.

Divya Pandey1, Kuldeep K Roy1

  • 1Department of Pharmaceutical Sciences, School of Health Sciences and Technology, UPES, Dehradun, 248007, Uttarakhand, India.

Archives of Biochemistry and Biophysics
|December 22, 2024
PubMed
Summary

KRAS G12C and G12D mutations are stabilized in their inactive states by inhibitors like AMG-510 and MRTX1133. Covalent AMG-510 more effectively locks KRAS G12C, stabilizing key amino acids in the Switch-II pocket.

Keywords:
CancerKRASKRAS inhibitorsMolecular dynamicsMutationRAS protein

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.6K

Related Experiment Videos

Last Updated: Jun 4, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.6K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • KRAS mutations, particularly G12C and G12D, are prevalent drivers of human cancers.
  • Previously considered undruggable, KRAS mutations are now targeted by specific inhibitors.
  • Understanding KRAS conformational dynamics is vital for developing effective cancer therapies.

Purpose of the Study:

  • To investigate how KRAS G12C and G12D mutations stabilize active states.
  • To elucidate the mechanism by which KRAS inhibitors lock mutated conformations in inactive states.
  • To compare the stabilizing effects of covalent (AMG-510) and non-covalent (MRTX1133) inhibitors.

Main Methods:

  • Multiple molecular dynamics (MD) simulations of wild-type and mutant KRAS.
  • Analysis of protein conformations, binding site dynamics, and Cα atom distances.
  • Per-residue energy decomposition to assess binding site stability.

Main Results:

  • GDP-bound KRAS G12C and G12D mutants were stabilized in inactive states by AMG-510 and MRTX1133, respectively.
  • Covalent AMG-510 demonstrated superior stabilization of KRAS G12C compared to non-covalent MRTX1133.
  • Inhibitor binding led to stable Cα atom distances and reduced energy variations in Switch-II pocket residues.

Conclusions:

  • KRAS inhibitors effectively lock oncogenic mutations in inactive conformations.
  • AMG-510's covalent binding provides enhanced stability to the KRAS G12C mutant.
  • These findings offer valuable insights for the design of novel KRAS-targeted cancer drugs.